Article Text
PDF
Summary
Drug-induced acute pancreatitis (DIAP) is a rare, but clinically significant diagnosis. Vedolizumab, an α4β7 integrin inhibitor, which was approved in 2015 for treatment of moderate to severe inflammatory bowel disease, is a well-tolerated medication with a favourable safety profile and minimal serious adverse events in premarketing clinical trials. We present the first reported case of acute pancreatitis directly attributable to vedolizumab.
- contraindications and precautions
- gastrointestinal system
- inflammatory bowel disease
Statistics from Altmetric.com
Footnotes
Contributors All authors were involved in the synthesis of the case report. SP was the primary author who reviewed the case notes, investigations, contacted the patient and wrote up the abstract and case presentation. KV and KS were involved in writing up the discussion and conclusions as well as editing the case report. MC performed the procedures referenced in the article and was involved in writing up the case presentation and discussion. All authors were involved in editing and reviewing the final document.
Competing interests None declared.
Patient consent Obtained.
Provenance and peer review Not commissioned; externally peer reviewed.